Gentamicin Sulfate Cream 0.1%

Manufacturer
Sola Pharmaceuticals
Effective date
2020-04-07
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
legacy-cache
Hydrated at
2026-08-01 23:37:00

Label at a glance#

ProductGentamicin Sulfate Cream 0.1%
Active ingredientGENTAMICIN SULFATE
Label structure9 sections

Indications and uses

Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Ge...

Dosage and administration

A small amount of Gentamicin Sulfate Cream should be applied gently to the lesions three or four times daily. The area treated may be covered with a gauze dressing if desired. In impetigo contagiosa, the crusts should be removed before application of gentamicin sulfate to permit maximum contact between the antibiotic and the infection. Care should be exercised to avoid further contamination of the infected skin. I...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Gentamicin Sulfate Cream is a wide spectrum antibiotic preparation for topical administration. Each gram contains Gentamicin Sulfate USP equivalent to 1 mg gentamicin base in a cream base containing stearic acid, propylene glycol monostearate, isopropyl myristate, polysorbate 40, propylene glycol, sorbitol solution and purified water with methylparaben and butylparaben as preservatives.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Gentamicin Sulfate is a wide spectrum antibiotic that provides highly effective topical treatment in primary and secondary bacterial infections of the skin. Gentamicin Sulfate Cream may clear infections that have not responded to treatment with other topical antibiotic agents. In primary skin infections such as impetigo contagiosa, treatment 3 or 4 times daily with Gentamicin Sulfate Cream usually clears the lesions promptly. In secondary skin infections, Gentamicin Sulfate Cream aids in the treatment of the underlying dermatoses

by controlling the infection. Bacteria susceptible to the action of gentamicin sulfate include sensitive strains of Streptococci (group A beta-hemolytic, alpha-hemolytic), Staphylococcus aureus (coagulase positive, coagulase negative, and some penicillinase-producing strains), and the gram-negative bacteria, Pseudomonas aeruginosa, Aerobacter aerogenes, Escherichia coli, Proteus vulgaris, and Klebsiella pneumoniae

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral

infections. Please Note: Gentamicin Sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin Sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the

treatment of infected stasis and other skin ulcers, infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with Gentamicin Sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical

antibiotic. Gentamicin Sulfate Cream is recommended for wet, oozing primary infections, and greasy, secondary infections, such as pustular acne or infected seborrheic dermatitis. If a water-washable preparation is desired, the cream is preferable. Gentamicin Sulfate Cream has been used successfully in infants over one year of age, as well as in adults and children.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

This drug product is contraindicated in individuals with a history of sensitivity to any of its components.

PERCAUTIONS

PRECAUTIONS SECTION

The use of topical antibiotics occasionally allows overgrowth of nonsusceptible organisms, including fungi. If this condition occurs, or if irritation, sensitization or superinfection develops, treatment with gentamicin sulfate should be discontinued and appropriate therapy instituted.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

In patients with dermatoses treated with Gentamicin Sulfate, irritation (erythema and pruritis) that did not usually require discontinuance of treatment has been reported in a small percentage of cases. There was no evidence of irritation or sensitization, however, in any of these patients patch-tested subsequently with Gentamicin Sulfate on normal skin. Possible photosensitization has been reported in several patients but could not be elicited in these patients by reapplication of Gentamicin Sulfate followed by exposure to ultraviolet radiation.

To report SUSPECTED ADVERSE REACTIONS, contact Teligent Pharma, Inc. at 1-856-697-1441, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

A small amount of Gentamicin Sulfate Cream should be applied gently to the lesions three or four times daily. The area treated may be covered with a gauze dressing if desired. In impetigo contagiosa, the crusts should be removed before application of gentamicin sulfate to permit maximum contact between the antibiotic and the infection. Care should be exercised to avoid further contamination of the infected skin. Infected stasis ulcers have responded well to treatment with gentamicin sulfate under gelatin packing.

HOW SUPPLIED

HOW SUPPLIED SECTION

Gentamicin Sulfate Cream USP, 0.1% is supplied as follows:

30 gram tube (NDC 70512-036-30)

Store at controlled room temperature 15°-30°C (59°-86°F).

Manufactured for:

SOLA Pharmaceuticals

Baton Rouge, LA 70810

C101322

PI-036-00

Rev 12/2019

Rev. 2

PACKAGE LABEL PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 70512-036-30

Gentamicin Sulfate

Cream USP, 0.1%

For Dermatological Use Only

Not for Ophthalmic Use

Keep this and all drugs out of the reach of children.

30 grams

Rx only

Sola Pharmaceuticals

Gentamicin Tube DisplayGentamicin Tube DisplayGentamicin Carton DisplayGentamicin Carton Display

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
70512-036-302022-01-28C16284748780-1d6a99b39-a2f9-a426-e053-dadaa90af4c2GENTAMICIN SULFATE CREAM USP, 0.1% For Dermatoligic Use Only Not for Opthalmic Use RX Only

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
70512-036-30GM - Gram70512-036d657fe41-d0e7-47ea-8f8e-c6023c89ad6a12020-07-13

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 12 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
70512-03670512-036-30

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 10 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog.

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2019-12-13 00:20 UTC2019-12A209304-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICALAT2019-10-1874a2ff9319b5…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A209304-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICALAT2019-10-1887673890dc5c…
2021-03-12 10:30 UTC2021-03A209304-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICALAT2019-10-185aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A209304-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICALAT2019-10-188869cabd3fbd…
2020-11-12 02:37 UTC2020-11A209304-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICALAT2019-10-18c0c555d07b60…
2019-12-14 00:12 UTC2019-12A209304-001GENTAMICIN SULFATEEQ 0.1% BASECREAM / TOPICALAT2019-10-183f01610625f2…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2019-12-13 00:20 UTC2019-12A209304-001AT174a2ff9319b5…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A209304-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A209304-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A209304-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A209304-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A209304-001AT13f01610625f2…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
a2b5d3ff-920e-280a-e053-2995a90ac84fa2b5d3ff-920d-280a-e053-2995a90ac84f2020-04-07Adverse reactionsExact identifier
spl id: a2b5d3ff-920e-280a-e053-2995a90ac84f
spl set id: a2b5d3ff-920d-280a-e053-2995a90ac84f

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.